Espana P, Chang P, Wiernik PH: Increased incidence of brain metastases in sarcoma patients. Cancer 45:377–380, 1980.
Mayer RJ, Berkowitz RS, Griffiths CT: Central nervous system involvement by ovarian carcinoma. A complication of prolonged survival with metastatic disease. Cancer 41: 776–783, 1978.
Nugent JL, Bunn PA, Jr, Mathews MJ et al.: CNS metastases in small cell bronchiogenic carcinoma. Increasing frequency and changing pattern with lengthening survival. Cancer 44:1885–1893, 1979.
Posner JB, Chernik NL: Intracranial metastases from systemic cancer. Adv Neurol 19:579–592, 1978.
Aronson SM, Garcia JH, Aronson BE: Metastatic neoplasms of the brain: Their frequency in relation to age. Cancer 17:558–563, 1964.
Zimm S, Wampler GL, Stablein D, Hazra T, Young HF: Intracerebral metastases in solid-tumor patients: Natural history and results of treatment. Cancer 48:384–394, 1981.
Posner JB: Management of central nervous system metastases. Semin Oncol 4:81–91, 1977.
Cairncross JG, Kim JH, Posner JB: Radiation therapy for brain metastases. Ann Neurol 7:529–541, 1980.
Deutsch M, Parsons JA, Mercado R, Jr: Radiotherapy for intracranial metastases. Cancer 34:1607–1661, 1974.
Marksbery WR, Books WH, Gupta GD, Young B: Treatment of patients with cerebral metastases. Arch Neurol 35:754–756, 1978.
Brogelt B, Gelber R, Kramer S et al.: The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiation Oncology Biol Phys 6:1–9, 1980.
Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS: The palliation of brain metastases in a favorable patient population: A randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiation Oncology Biol Phys 7:891–895, 1981.
White KT, Fleming TR, Lows ER: Single metastases to the brain- Surgical treatment in 122 consecutive patients. Mayo Clin Proc 56:424–428, 1981.
Chapman JD, Reuvers AP, Borsa J et al.: Nitroheterocytic drugs as selective radiosensitizers of hypoxic mammalian cells. Cancer Chemother Rep 58:559–570, 1974.
Urtasun R, Band P, Chapman JD et al.: Radiation and high-dose metronidazole in supratentorial glioblastomas. New Engl J Med 294:1364–1367, 1976.
Kaplan EL, Meier P: Nonparametic estimation from incomplete observations. J Am Stat Assoc 53:457–481, 1958.
Gehan EA: A generalized Wilcoxin test for comparing arbitrarily singly-censored samples. Biometricha 52:203–223, 1965.
Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Rep 50:163–170, 1966.
Phillips TL, Wasserman TH, Johnson RJ et al.: Final report on the United States phase I clinical trial of the hypoxic cell radiosensitize, misonidazole (Ro-70–0582; NSC #261037). Cancer 48:1697–1704, 1981.
Ang KK, VanderScheneren E, Notter G et al.: Split course multiple daily fractionated radiotherapy schedule combined with misonidazole for management of grade III and grade IV glioma. A pilot feasability study of the radiotherapy group of EORTC. Int J Radiation Oncology Biol Phys 8:1657–1664, 1982.
Madojewicz S, West CR, Park HC et al.: Phase II study-intra-arterial BCNU therapy for metastatic brain tumors. Cancer 47:653–657, 1981.
Salcman M, Samaros GM: Hyperthermia for brain tumors: Biophysical rational. Neurosurgery 9:327–335, 1981.
Neuwelt EA, Diehl JT, Vu LH et al.: Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. Ann Intern Med 94:449–454, 1981.